Functional Analysis and Therapeutic Targeting of STAG2 Mutations in Ewing sarcoma |
Georgetown University / Todd Waldman, MD, PhD |
Innovation Grants |
2015 |
District of Columbia |
Preclinical Development of Atr Inhibitor VE-822, Delivered Systemically in Nanoparticles, for Medulloblastoma Therapy |
University of North Carolina / Timothy Gershon, MD, PhD |
Innovation Grants |
2015 |
North Carolina |
Transcriptional Effectors of Activated RAS Signaling in Juvenile Myelomonocytic Leukemia |
Boston Children’s Hospital / Alan Cantor, MD, PhD |
Innovation Grants |
2015 |
Massachusetts |
Small Molecule Inhibitors of ERG for Pediatric Leukemia and Sarcoma |
University of Virginia, School of Medicine / John Bushweller, PhD |
Innovation Grants |
2015 |
Virginia |
Regulation of Tumor Debris Mediated Inflammation as a Therapeutic Modality in Medulloblastoma |
Dana-Farber Cancer Institute / Mark Kieran, MD, PhD & Dipak Panigrahy, MD |
Innovation Grants |
2015 |
Massachusetts |
High-dimensional Biochemical CyTOF Analysis of Pediatric T cell Leukemias |
University of California San Francisco / Jeroen Roose, PhD |
Innovation Grants |
2015 |
California |
Identifying Epigenetic Mechanisms Impacting Neuroblastoma Genome Stability and Drug Response |
Massachusetts General Hospital / Johnathan Whetstine, PhD |
Innovation Grants |
2015 |
Massachusetts |
Identifying how Pre-existing Anti-Therapeutic Antibodies (PATA) are Associated with Better Outcome in a Clinical Trial of ADCC-inducing Anti-GD2 mAb |
University of Wisconsin - Madison / Paul Sondel, MD, PhD |
Innovation Grants |
2015 |
Wisconsin |
Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma |
Virginia Commonwealth University / Anthony Faber, MD & Yael Mosse, MD (CHOP) |
Innovation Grants |
2015 |
Virginia |
Synergistic Differentiation Therapy in Neuroblastoma |
Duke University / Gerard Blobe, M.D./Ph.D |
Innovation Grants |
2015 |
North Carolina |